Caraco's manufacturing facility and executive offices were constructed in 1991, after a $9.1 million loan from the Economic Development Corporation of the city of Detroit. Since August 1997, capital infusions and loans have primarily come from Sun Pharma. Sun Pharma has also acted as a guarantor on loans to Caraco, has supplied the corporation with raw material for certain products, assisted in obtaining machinery and equipment to enhance production capacities, and has transferred certain generic products. Sun Pharma's investment in and support of Caraco has resulted in, since the second quarter of 2002, Caraco achieving the sales to support its operations. As of June 2011, Sun Pharma owns 100% on a diluted basis, of the outstanding common shares of Caraco.
In 2004, Sun Pharma acquired the trademarks, manufacturing know'how and other intellectual property of some brands from Women's First Healthcare, Inc, These products were later assigned to Sun Pharma Inc.
In December 2005, Sun Pharma Inc completed the purchase of dosage from manufacturing operations of Able Labs for USD 23.15 million. This facility has the capacity to make controlled substance dosage forms.
Sun Pharmaceutical (Bangladesh)
Sun Pharmaceutical (Bangladesh) is a private limited company, owns and operates a pharmaceutical factory and makes pharmaceutical products that are sold in the local market. The company began commercial operations in 2004.
This is partnership between Sun Pharma/ subsidiaries and City Overseas Ltd, a company incorporated in Bangladesh.
Alkaloida Chemical Company Exclusive Group Ltd.
ICN Hungary, purchased from Valeant Pharmaceuticals in 2005, is one of the few units worldwide, authorized to make controlled substances. ICN Hungary has now been renamed Alkaloida Chemical Company. This 170 acre site has facilities spread over 1,75,000 sq ft for the manufacture of bulk actives, with 500 KL capacity and designated areas to make controlled substances. It has a 150,000 sq ft facility for different dosage forms such as film coated and effervescent tablets, capsules, etc. A large 65,000 sq ft research center has labs across synthetic chemistry, instrumentation analytical and structural elucidation. The site is operational with 450 people and additional recruitments are planned over time
Chattem Chemicals
In 2008, Sun Pharma Inc. acquired Chattem Chemicals, Inc. a Chattanooga, Tennessee-based narcotic raw material importer and a DEA licensed API manufacturer of controlled substances.
Sun Pharma acquired a controlling stake in Taro in September 2010 after completing an option agreement first entered into in 2007 with the controlling shareholders of Taro. Sun's subsidiaries have subsequently increased their economic interest in Taro to 66%. Taro has an established franchise in dermatology and topical products in the US, in addtion to other generic products. Taro has sales and marketing operations in Israel and Canada.
News Articles
Contact Us
